Get the app
USHealthcare

Aktis Oncology, Inc. Common stock (AKTS)

US · Healthcare · Biotechnology

$22.86+0.66%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$3.4M
Revenue YoY
+111.4%
Net profit
$-24.1M
EPS
$-0.44
EPS estimate
$-0.44
Net margin
-713.5%

EPS came in at -0.44 against a street estimate of -0.44 — a beat of 0.0%.

Key statistics

Market cap
$1.33B
Forward P/E
0.0
P/B
2.76
Book value
$8.76
EPS (TTM)
$-1.32
52-week high
$34.19
52-week low
$14.72
50-day MA
$25.38
200-day MA
$21.54

Analyst view

with an average price target of $34.81.

Shareholding

Insiders
14.05%
Institutions
72.90%

Largest institutional holders

FundStake
MPM Oncology Impact Management LP8.69%
EcoR1 Capital, LLC8.67%
Blue Owl Capital Holdings LP5.52%
T. Rowe Price Investment Management,Inc.3.82%
BlackRock Inc3.80%
Wellington Management Company LLP3.54%
RTW INVESTMENTS, LLC2.86%
T. Rowe Price Associates, Inc.2.81%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
AKTIS ONCOLOGY, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $82.5 million in cash and cash equivalents as of June 30, 2026; $434
2026-08-13
Results announced · Q3 2026
AKTIS ONCOLOGY Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position of $517.3 million as of June 30, 2026 (up from $226.8 million at D
2026-08-13
Quarterly report · Q1 2026
AKTIS ONCOLOGY, INC. - 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $371.6 million in cash and equivalents plus $166.9 million in market
2026-05-11
Results announced · Q2 2026
AKTIS ONCOLOGY, INC. – Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $538.5 million as of March 31, 2026, up $311.7 million fr
2026-05-11
Board / officer change · Q2 2026
AKTIS ONCOLOGY, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Glenn Gormley, MD, PhD (age 72) appointed as Class I director effective April 15,
2026-04-16
Annual report FY2025
AKTIS ONCOLOGY, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Clinical-stage oncology company, not yet profitable, no approve
2026-03-30
Results announced · Q1 2026
AKTIS ONCOLOGY, INC. – COMPANY SUMMARY HEADLINE NUMBERS • Cash position (pro forma): $562.1 million as of December 31, 2025, after including $335.3
2026-03-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aktis Oncology, Inc. Common stock — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.